PCME is an accredited provider specializing in innovative continuing medical education solutions.
PCME is an accredited provider specializing in innovative continuing medical education solutions.
The benefits of treating dyslipidemia to reduce CVD risk have been clearly demonstrated in a number of clinical trials in chronic atherosclerosis. But there is growing uncertainty regarding exactly how this CVD risk reduction is mediated. What is the relative importance of LDL reduction and reduction of anti-inflammatory markers? How important are plaque stabilization and actual atherosclerotic plaque reduction in reducing CVD risk? These questions define an important educational gap, and there is a clear need for education to bridge the gap between what is currently known about reducing CVD risk, and the appropriate application of new insights into clinical practice.
This program is intended to inform physicians about new insights regarding the therapeutic avenues for CVD risk reduction. It will also provide physicians with the latest informed thinking about how to incorporate these emerging therapeutic insights into clinical practice, in order to better protect at-risk patients from adverse CVD events.
Christie M. Ballantyne, MD (Chair)
Professor of Medicine
Chief, Section of Atherosclerosis and Vascular Medicine
Director, Center for Cardiovascular Prevention
Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center
Houston, TX
Michael H. Davidson, MD, FACC, FACP
Clinical Professor
Director, Preventive Cardiology
Associate Vice Chairman, Continuing Medical Education
The University of Chicago Pritzker School of Medicine
Executive Medical Director, Radiant Research
Chicago, IL
Peter Ganz, MD
Chief, Division of Cardiology
Director, Center of Excellence in Vascular Research
San Francisco General Hospital
Maurice Eliaser Jr. Distinguished Professor of Medicine
University of California
San Francisco, CA
Roger S. Blumenthal, MD, FACC, FAHA
Professor of Medicine
Johns Hopkins School of Medicine
Director, Ciccarone Center for the Prevention of Heart Disease
Johns Hopkins Hospital
Baltimore, MD
This program is intended for cardiologists and other health care professionals.
This activity was designed to address the following IOM competencies: employ evidence-based practice.
At the conclusion of this activity, participants should be able to:
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this educational activity for a maximum of 2.0 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Christie M. Ballantyne, MD: Grant/research support: Abbott; AstraZeneca; GlaxoSmithKline; Merck and Company; Pfizer; Schering-Plough; Sanofi-Synthelab; Takeda Consultant: Abbott; AstraZeneca; Atherogenics; GlaxoSmithKline; Merck and Company; Merck-Schering Plough; Novartis; Pfizer; Sanofi-Synthelabo; Schering-Plough; Takeda; Speakers' bureau/honoraria: AstraZeneca; GlaxoSmithKline; Merck and Company; Merck-Schering Plough; Pfizer; Pfizer Schering-Plough; Reliant
Michael H. Davidson, MD, FACC, FACP: Speakers' Bureau: Abbott Laboratories; AstraZeneca Pharmaceuticals; Daiichi-Sankyo; diaDexus, Inc.; Merck & Co., Inc.; Merck/Schering-Plough; Oscient Pharmaceuticals; Pfizer Laboratories; Takeda; Cousultant: Abbott Laboratories; AstraZeneca Phannaceuticals; Daiichi-Sankyo, Inc.; diaDexus, Inc.; Merck & Company; Merck/Schering-Plough; Pfizer Laboratories; Roche Pharmaceuticals; Sanofi-Aventis; Synarc; Takeda; Grant Research: Abbott Laboratories; AstraZeneca Pharmaceuticals; Daiichi-Sankyo, Inc.; Merck & Company; Merck/Schering-Plough; Pfizer Laboratories; Roche Pharmaceuticals; Takeda; Advisory Board: Abbott Laboratories; Access Health; AstraZeneca Pharmaceuticals; Atherogenics; Daiichi Sankyo; Kinemed; Merck & Company; Merck/Schering-Plough; Oscient Pharmaceuticals; Pfizer Laboratories; PreEmptive Meds (Scientific Advisory Board); Roche Pharmaceuticals; Takeda; Xinthria Pharmaceuticals (Scientific Advisory Board); Equity/Board of Directors: Angiogen (Board of Directors); Sonogene (Board of Directors); Professional Evaluation, Inc; Medical Education Company (Board of Directors)
Peter Ganz, MD: Consultant: Pfizer; Gilead; Genentech; Speaker: Pfizer
Roger S. Blumenthal, MD, FACC, FAHA: Nothing to Disclose
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Barry Watkins, PhD; Brad Pine; Donna Fucello; Blair St. Amand; Dana Simpler, MD: Nothing to Disclose
| Sponsored by |
Supported by an educational grant from |
By clicking this button you are agreeing that you have read and understood the CME Statements above.
This event is not part of the official ACC Annual Scientific Session and/or the ACC's Innovation in Intervention: i2 Summit in Partnership with the Cardiovascular Research Foundation, as planned by their Program Committees.
